Tag Archive for: Clinical Trial

Rejuvenate Biomed announces publication of data showing that RJx-01 significantly increases muscle mass, muscle strength and physical performance in sarcopenia mouse models

/in

Sarcopenia – age-related loss of muscle mass and strength – affects up to 1 in 5 elderly people globallyi but there are no approved drugs The newly-published data validate the predictive value of Rejuvenate Biomed’s proprietary drug discovery platforms and have accelerated the advancement of RJx-01 into an ongoing 6-week placebo-controlled trial in human volunteers Diepenbeek, […]

Read more

Acesion Pharma Announces Positive Pre-Clinical Data for AP31969

/in

Copenhagen, Denmark – Acesion Pharma (“Acesion” or “the Company”), a biotech company pioneering first-in-class novel therapies for atrial fibrillation (“AF”), the most common cardiac arrhythmia, today announces positive data from pre-clinical studies with AP31969, its second-generation oral SK channel inhibitor developed for chronic oral maintenance treatment to prevent AF recurrence. Acesion aims to develop a […]

Read more

Vicore initiates clinical proof-of-concept study of endothelial dysfunction

/in

Stockholm, May 3, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), today announces the first patient dosed with C21 in a clinical study of endothelial dysfunction. Endothelial dysfunction is a key driver of organ damage associated with […]

Read more

Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon[®] in IgA Nephropathy

/in

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced positive topline results from the global, randomized, double-blind, placebo-controlled Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon (TARPEYO®/Kinpeygo® (budesonide) delayed release capsules) versus placebo in patients with primary IgA nephropathy (IgAN). The trial met its primary endpoint with Nefecon demonstrating a highly […]

Read more

vasopharm GmbH Announces Brain Glutamate Microdialysate Data from Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury

/in

Ronopterin significantly reduces glutamate levels measured in brain microdialysate from TBI patients, an important and long sought indicator of biochemical neuroprotection Combined inhibition of nitric oxide synthesis and glutamate increase expands our understanding of Ronopterin’s mode of action and its association with improved outcome in TBI Decreasing glutamate adds to the previously reported reduction in […]

Read more